Trilogy Transcatheter Heart Valve System
JenaValve Technology, Inc. · Decision date Jul 9, 2026
What did the FDA decide?
FDA records P250024/S003 as a supplement to PMA P250024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 9, 2026.
FDA approval order statement
a modification to the receiving inspection sampling plan for delivery system components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 9, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P250024/S003
- Regulatory pathway
- PMA supplement
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- Decision code
- OK30
- Decision date
- Jul 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250024 · Original PMA
Trilogy Transcatheter Heart Valve System
P250024/S001 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S002 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S003 received
Application receipt date recorded by FDA.
P250024/S003 · FDA decision
30-Day Notice
P250024/S006 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S005 · Related supplement
Trilogy Transcatheter Heart Valve System
Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| JenaValve Technology, Inc. | PMA approval | Mar 17, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S001 | JenaValve Technology, Inc. | PMA supplement | May 18, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S002 | JenaValve Technology, Inc. | PMA supplement | May 18, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
JenaValve Technology, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Cromwell, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250024/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
